Holen Sie sich die Stockscreener-App
3.69
2.38%
-0.09
Handel nachbörslich:
3.70
0.01
+0.27%
Schlusskurs vom Vortag:
$3.78
Offen:
$3.79
24-Stunden-Volumen:
410.74K
Relative Volume:
0.36
Marktkapitalisierung:
$234.55M
Einnahmen:
$157.08M
Nettoeinkommen (Verlust:
$-70.36M
KGV:
-3.3195
EPS:
-1.1116
Netto-Cashflow:
$-71.69M
1W Leistung:
-0.27%
1M Leistung:
-20.13%
6M Leistung:
+101.64%
1J Leistung:
+136.54%
1-Tages-Spanne:
$3.61
$3.795
1-Wochen-Bereich:
$3.61
$4.06
52-Wochen-Spanne:
$1.29
$5.08
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.69 | 254.25M | 157.08M | -70.36M | -71.69M | -1.1116 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important (MGNX) - Seeking Alpha
Citizens reiterates MacroGenics stock rating ahead of ESMO data - Investing.com
Citizens reiterates MacroGenics stock rating ahead of ESMO data By Investing.com - Investing.com Canada
MacroGenics Inc (MGNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MacroGenics Inc (MGNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MacroGenics, Inc. Revenue Breakdown – NASDAQ:MGNX - TradingView
MGNX|MacroGenics Inc|Price:3.700|Chg%:-0.310 - TradingKey
MacroGenics Inc (MGNX) Cash Flow - TradingKey
MacroGenics, Inc. Revenue Breakdown – DUS:M55 - TradingView
TradingKey - TradingKey
MacroGenics slips on trial data for lead asset (MGNX:NASDAQ) - Seeking Alpha
MacroGenics Inc (MGNX) Institutional Confidence - TradingKey
MacroGenics’ MGC026 meets Phase 1 trial milestone in SCCHN - Investing.com
MacroGenics (MGNX) Advances Phase 1 Study of MGC026 - GuruFocus
MacroGenics’ MGC026 meets trial threshold in head and neck cancer By Investing.com - Investing.com Nigeria
MacroGenics Advances MGC026 in Phase 1 Oncology Trial - TipRanks
MacroGenics’ MGC026 meets trial threshold in head and neck cancer - Investing.com
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 - The Manila Times
Entera Bio Leads Our Top 3 Penny Stocks To Consider - Sahm
MGNX stock holds focus as MacroGenics plans and pipeline metrics matter - Ad-hoc-news.de
MacroGenics (MGNX): Millennium group discloses 3.7% beneficial stake in amended 13G - Stock Titan
MacroGenics stock gains after FDA priority review as revenue rises and cash runway extends - Ad-hoc-news.de
MacroGenics Inc (NASDAQ: MGNX) Share Price, MGNX Stock News, MGNX Share Price & Updates - Kalkine
[144] MACROGENICS INC SEC Filing - Stock Titan
Form 144 MACROGENICS For: 13 July By Investing.com - Investing.com Nigeria
MacroGenics (MGNX) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
MGNX Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Pipeline DevelopmentOperating Margin Analysis - dars.gov.et
MacroGenics, Inc. 8-K SEC Filing July 2026: Company Details, Stock Info, and Key Regulatory Disclosures - Minichart
MacroGenics (MGNX) Slides Further as Stock Hovers Near Key Support LevelsTime Weighted Price - DonanımHaber
MacroGenics announces upcoming board change with director resignation - TipRanks
Karen Ferrante to Resign from MacroGenics' Board Effective Sept 1, 2026 - TradingView
Board member Karen Ferrante to leave MacroGenics (MGNX) board in September 2026 - Stock Titan
Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026 - marketscreener.com
MacroGenics Inc highlights its oncology pipeline as investors track future catalysts - Ad-hoc-news.de
MacroGenics Sells GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million - Minichart
MacroGenics Completes Asset Sale, Shifts to R&D Focus - TipRanks
MacroGenics (NASDAQ: MGNX) nets $110.7M and gain in CDMO sale - Stock Titan
Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Mfg. Ops - Contract Pharma
Bora Pharmaceuticals completes $122.5M buy of MacroGenics manufacturing operations - megaproject.com
M55 Forecast — Price Target — Prediction for 2027 - TradingView
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing OperationsBrand Spur - Brand Spur
MacroGenics completes sale of manufacturing operations to Bora By Investing.com - Investing.com Australia
MacroGenics completes sale of manufacturing operations to Bora - Investing.com
MacroGenics sells its drug-making operations to Bora for $122.5M - Stock Titan
Bora Pharmaceuticals Completes Acquisition Of Macrogenics' Rockville Manufacturing Operations - Menafn
Macrogenics | 4: Statement of changes in beneficial ownership of securities-Director O'Brien Federica F. - Moomoo
MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2500 Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2000 Value Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2000 Growth Benchmark - marketscreener.com
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Macrogenics Inc-Aktie (MGNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Koenig Scott | Director |
Feb 15 '26 |
Option Exercise |
0.00 |
21,165 |
0 |
867,240 |
| HEIDEN WILLIAM K | Director |
Aug 19 '25 |
Buy |
1.52 |
50,500 |
76,760 |
61,500 |
| HEIDEN WILLIAM K | Director |
Aug 20 '25 |
Buy |
1.49 |
49,500 |
73,755 |
111,000 |
| Koenig Scott | Director |
Aug 13 '25 |
Option Exercise |
0.00 |
52,829 |
0 |
830,244 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):